Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

OXFORD, United Kingdom, June 21, 2023 -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical t...

Related Keywords

Ankara ,Turkey ,New York ,United States ,United Kingdom ,Austria ,Vienna ,Wien ,Meg Marshall ,Jonothan Blackbourn ,Laura Cameron ,Eleanor Barnes ,Hepatitisb Foundation ,Oxford University Press ,Nasdaq ,Arbutus Biopharma Corporation ,Hbsag Group ,Oxford University ,University Of Oxford ,Health Information For International ,Centers For Disease ,Experimental Medicine At Oxford University ,Astrazeneca ,International Liver Congress ,Exchange Commission ,European Association ,Experimental Medicine ,Chief Medical ,Hepatitisb Surface Antigen ,Professor Eleanor ,Modified Vaccinia Ankara ,East Asia ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Disease Control ,Health Information ,